Literature DB >> 1816558

Structure-activity relationships at 5-HT1A receptors: binding profiles and intrinsic activity.

D L Nelson1.   

Abstract

The 5-HT1A receptor has been one of the most studied 5-HT receptor subtypes in terms of its pharmacologic profile. Comparisons of various studies of structure-activity relationships (SAR) at this receptor shows an emerging profile for this receptor's pharmacophore. The present discussion focuses on the findings generated with relatively small molecules that can be considered as analogs of serotonin itself and that illustrate some of the structural properties that are important for high-affinity recognition by the receptor. Most of the SAR work has been based on the affinities of compounds for the receptor as determined by the radioligand-binding technique, which has a significant limitation in that it cannot define the intrinsic activity of compounds at the receptor. This problem can be addressed by functional assays, and an example of SAR at the 5-HT1A receptor-coupled adenylate cyclase system is provided.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1816558     DOI: 10.1016/0091-3057(91)90124-k

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes.

Authors:  Claudio A Villalobos; Paulina Bull; Patricio Sáez; Bruce K Cassels; J Pablo Huidobro-Toro
Journal:  Br J Pharmacol       Date:  2004-03-08       Impact factor: 8.739

2.  Synthesis of conformationally constrained aryl- or heteroarylpiperazinyl derivatives of selected imides as 5-HT1A receptor ligands.

Authors:  Jerzy Kossakowski; Mariola Krawiecka; Bozena Kuran
Journal:  Molecules       Date:  2006-08-23       Impact factor: 4.411

3.  Model structure-activity relationship studies of potential tropane 5HT1A, 5HT2A, and D2 receptor ligands.

Authors:  Tomasz Słowiński; Jacek Stefanowicz; Martyna Z Wróbel; Franciszek Herold; Andrzej Mazurek; Franciszek Pluciński; Aleksander P Mazurek; Irena Wolska
Journal:  Med Chem Res       Date:  2012-11-11       Impact factor: 1.965

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.